Screener
Taysha Gene Therapies, Inc. TSHA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $0-100% | $5.49M+171% | $0-100% | $1.99M+78.6% | ||
| $38.64M+91.8% | $33.81M+117% | $24.95M+62.8% | $25.75M+72.3% | $20.14M+33.6% | ||
| $12.15M+41.3% | $9.68M+18.6% | $8.83M+33.2% | $8.28M+4.8% | $8.6M+17.2% | ||
| $47.35M+64.8% | $43.49M+83.3% | $33.79M+53.9% | $34.02M+22.9% | $28.74M+28.2% | ||
| -$47.35M-77.0% | -$43.49M-103% | -$28.3M-42.0% | -$34.02M-31.4% | -$26.75M-25.6% | ||
| $6K-64.7% | $9K-52.6% | $12K-45.5% | $15K-37.5% | $17K-37.0% | ||
| $710K+650% | $1.08M+1,096% | $449K-60.9% | $1.29M+245% | -$129K-135% | ||
| -$46.64M-73.5% | -$42.41M-97.0% | -$27.85M-48.3% | -$32.73M-28.2% | -$26.88M-28.4% | ||
| -$0.13-44.4% | -$0.12-50.0% | -$0.08-14.3% | -$0.09+10.0% | -$0.090.0% | ||
| -$46.95M-77.5% | -$43.19M-104% | -$28M-42.7% | -$33.82M-32.1% | -$26.45M-26.0% | ||
| -$47.35M-77.0% | -$43.49M-103% | -$28.3M-42.0% | -$34.02M-31.4% | -$26.75M-25.6% |
FAQ
- What is Taysha Gene Therapies, Inc.'s revenue?
- Taysha Gene Therapies, Inc. (TSHA) generated $5.5M in revenue over the trailing twelve months, down 32.3% year over year.
- Is Taysha Gene Therapies, Inc. profitable?
- Taysha Gene Therapies, Inc. is not currently profitable: it reported a net loss of $149.6M over the trailing twelve months, a -2728.0% net margin.
- What is Taysha Gene Therapies, Inc.'s earnings per share?
- Taysha Gene Therapies, Inc.'s diluted EPS over the trailing twelve months is $-0.42.
- Where does Taysha Gene Therapies, Inc.'s income statement data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
